The market for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatal, has attracted many of biopharma’s biggest names.
Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen), Roche’s (ROG: SIX) Evrysdi (risdiplam) and Novartis’ (NOVN: VX) Zolgensma (onasemnogene abeparvovec) are already competing in a market predicted to be worth nearly $2.1 billion by 2026, according to Stratview Research.
But it is not just big pharma players seeking to gain a share of the growing market, with Boston, USA-based biotech Scholar Rock (Nasdaq: SRRK) hopeful of advancing apitegromab, a selective inhibitor of the activation of myostatin which is now being studied in a Phase III study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze